Literature DB >> 3174541

Treatment of hypercalcaemia in thyrotoxicosis with aminohydroxypropylidene diphosphonate.

T T Tan1, A A Alzaid, N Sutcliffe, M D Gardner, J A Thomson, I T Boyle.   

Abstract

Two patients had symptomatic hypercalcaemia accompanying thyrotoxicosis, despite initial treatment with volume repletion, beta blockade and antithyroid drugs. They were further managed with intravenous infusions of aminohydroxypropylidene diphosphonate resulting in rapid normalization of the serum calcium, with relief of symptoms. Aminohydroxypropylidene diphosphonate effectively suppressed the increased bone resorption of thyrotoxicosis without any undesirable adverse effects.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3174541      PMCID: PMC2428854          DOI: 10.1136/pgmj.64.749.224

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  14 in total

1.  The effect of thyroid disease on calcium metabolism in man.

Authors:  S M KRANE; G L BROWNELL; J B STANBURY; H CORRIGAN
Journal:  J Clin Invest       Date:  1956-08       Impact factor: 14.808

2.  Treatment of thyrotoxic hypercalcemia with propranolol.

Authors:  R K Rude; S B Oldham; F R Singer; J T Nicoloff
Journal:  N Engl J Med       Date:  1976-02-19       Impact factor: 91.245

3.  Investigation of bone and mineral metabolism in hyperthyroidism before and after treatment using calcitonin, 47Ca and balance studies.

Authors:  J T Hendriks; D Smeenk
Journal:  Acta Endocrinol (Copenh)       Date:  1979-05

4.  Hypercalcemia of thyrotoxicosis.

Authors:  J D Baxter; P K Bondy
Journal:  Ann Intern Med       Date:  1966-09       Impact factor: 25.391

5.  Thyrotoxic hypercalcaemia treated with porcine calcitonin.

Authors:  R M Buckle; A M Mason; J E Middleton
Journal:  Lancet       Date:  1969-06-07       Impact factor: 79.321

6.  Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer.

Authors:  B M Cantwell; A L Harris
Journal:  Br Med J (Clin Res Ed)       Date:  1987-02-21

7.  Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy.

Authors:  S H Ralston; I Fogelman; M D Gardiner; I T Boyle
Journal:  Br Med J (Clin Res Ed)       Date:  1984-05-12

8.  Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.

Authors:  S H Ralston; M D Gardner; F J Dryburgh; A S Jenkins; R A Cowan; I T Boyle
Journal:  Lancet       Date:  1985-10-26       Impact factor: 79.321

9.  Symptomatic hypercalcaemia in thyrotoxicosis.

Authors:  R G Twycross; V Marks
Journal:  Br Med J       Date:  1970-06-20

10.  Direct stimulation of bone resorption by thyroid hormones.

Authors:  G R Mundy; J L Shapiro; J G Bandelin; E M Canalis; L G Raisz
Journal:  J Clin Invest       Date:  1976-09       Impact factor: 14.808

View more
  4 in total

1.  Causes of anorexia in untreated hyperthyroidism: a prospective study.

Authors:  W X Dai; X W Meng
Journal:  Postgrad Med J       Date:  2000-05       Impact factor: 2.401

Review 2.  Medical management of hypercalcaemia.

Authors:  S H Ralston
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

Review 3.  Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  A Fitton; D McTavish
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

4.  Clinical experience with pamidronate in the treatment of Paget's disease of bone.

Authors:  S J Gallacher; B F Boyce; U Patel; A Jenkins; S H Ralston; I T Boyle
Journal:  Ann Rheum Dis       Date:  1991-12       Impact factor: 19.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.